Cardio-oncology & otherCohort study
Cardiovascular Disease Risk in Adults With Hematological Malignancies
- Matched cohort study
- population-based
- registry-linked
- general population matched controls
Authors' conclusion
Patients and survivors of hematological malignancies face substantially elevated short- and long-term risk of CVD compared with the general population, varying markedly by malignancy subtype.
Study context
- Population
- Adults (≥18 years) with hematological malignancies, Netherlands Cancer Registry 1995–2023
- Participants
- 174,984 vs 855,085
- Exposure
- Hematological malignancies vs matched general population controls
- Hematological malignanciesn = 174,984
- Controln = 855,085reference
- Outcome
- Short- and long-term incidence of cardiovascular disease (CVD) (11 CV outcomes)
Main finding
As reported in the abstract
HF excess rate per 1,000 person-years
- Myelodysplastic syndrome · highest HF excess rate
- excess rate per 1,000 person-years 37.75 (95% CI 35.60–39.90)
- Multiple myeloma · HF
- excess rate per 1,000 person-years 24.68 (95% CI 23.46–25.90)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| DVT, first year — Chronic lymphocytic leukemia vs Control · lowest | 3.52 (2.58–4.80) | |
| DVT, first year — Hodgkin lymphoma vs Control · highest | 34.04 (19.83–58.44) | |
| 0.050.21520Hazard ratio (log scale) |
VTE · up to 5 years
- VTE risk peaked within first year after diagnosis and remained elevated up to 5 years across all malignancies
Original publication
Cardiovascular Disease Risk in Adults With Hematological Malignancies. J Am Coll Cardiol. Published 8 April 2026. doi:10.1016/j.jacc.2026.02.5089
Summarised from the published abstract; every number is checked against it